NEW YORK (GenomeWeb News) – NanoString Technologies has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the firm to sell the test in the European Union and other countries that recognize the CE Mark. The test provides a subtype classification based on the fundamental biology of an individual's breast tumor and a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early-stage breast cancer who have been treated with hormonal therapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.